Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Aventis Pharmaceuticals committed to fund ImmunoGen $18.2 million in research support over the twelve months beginning September 1, 2006, in addition to…
Sanofi-aventis licensed expanded access to ImmunoGen's TAP technology, broadening the existing collaboration first established in 2003.
Sanofi terminated tusamitamab ravtansine (SAR408701) in December 2022 after Phase 3 NSCLC futility, scrapping a top ADC prospect after the study setback.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Sanofi-Aventis extends antibody-drug conjugate (ADC/TAP) research collaboration with ImmunoGen; extension begins Sept 2006 with additional committed funding. Strategically notable ADC platform deal.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi-Aventis / ImmunoGen Inc. (this deal) | 2005 | $18M | — |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Sanofi-Aventis / Merial Limited (Merck's 50% interest) | 2009 | $4.0B | 65 |
| Sanofi-Aventis / Acambis plc | 2008 | $548M | 36 |
| Sanofi-Aventis / Shantha Biotechnics Limited | 2009 | $784M | 34 |
| Sanofi-Aventis / Fovea Pharmaceuticals SA | 2009 | $541M | 23 |
| Sanofi-Aventis / BiPar Sciences, Inc. | 2009 | $500M | 8 |
← Browse all deals · How we score deals
More: 2005 deals · Sanofi-Aventis deals